$31.00 Million in Sales Expected for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) This Quarter

Brokerages forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report $31.00 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $20.00 million and the highest estimate coming in at $42.00 million. Arrowhead Pharmaceuticals posted sales of $34.66 million in the same quarter last year, which indicates a negative year over year growth rate of 10.6%. The company is expected to announce its next quarterly earnings results on Thursday, February 6th.

On average, analysts expect that Arrowhead Pharmaceuticals will report full-year sales of $86.87 million for the current fiscal year, with estimates ranging from $53.00 million to $128.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $75.08 million, with estimates ranging from $40.00 million to $116.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). The business had revenue of $43.29 million for the quarter, compared to analysts’ expectations of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%.

Several research analysts have weighed in on the stock. Robert W. Baird raised shares of Arrowhead Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $39.00 to $70.00 in a research note on Monday, November 25th. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, October 9th. B. Riley reissued a “buy” rating and issued a $83.00 price target (up from $59.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 27th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 price objective (up from $24.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 19th. Finally, S&P Equity Research restated a “buy” rating on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 26th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Pharmaceuticals has a consensus rating of “Buy” and an average target price of $72.80.

Shares of ARWR opened at $67.77 on Tuesday. The company’s 50-day moving average price is $50.25 and its 200 day moving average price is $34.28. Arrowhead Pharmaceuticals has a 12-month low of $10.41 and a 12-month high of $73.72. The firm has a market cap of $6.44 billion, a P/E ratio of 98.22 and a beta of 1.98.

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 4,250 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $29.00, for a total transaction of $123,250.00. Following the sale, the chief executive officer now directly owns 2,146,153 shares in the company, valued at $62,238,437. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 85,000 shares of the stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $30.00, for a total transaction of $2,550,000.00. Following the sale, the director now directly owns 121,000 shares in the company, valued at approximately $3,630,000. The disclosure for this sale can be found here. Insiders sold 288,071 shares of company stock valued at $10,518,443 over the last ninety days. Insiders own 4.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 96.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after buying an additional 500 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals during the second quarter worth $34,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $368,000. Pearl River Capital LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $111,000. Finally, Riverhead Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the second quarter valued at $148,000. Hedge funds and other institutional investors own 70.39% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Read More: What is the formula for the cash asset ratio?

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.